Spark Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Revenues
Product
Contract Revenue
Total revenues
Operating expenses:
Cost of goods sold
Product
Contract Revenue
Research and development
Acquired in-process research and development
Impairment of acquired in-process research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Interest income
Unrealized loss on equity investments
Interest income, net
Other income
Loss before income taxes
Income tax benefit (expense)
Net loss
Preferred stock dividends
Net loss applicable to common stockholders
Basic and diluted net loss per common share (in usd per share)
Weighted average basic and diluted common shares outstanding (in shares)
Other comprehensive income (loss):
Unrealized (loss) gain on available-for-sale securities
Unrealized loss on interest rate swap
Foreign exchange translation adjustment
Total comprehensive loss

Comments